The acquisition activity by Casdin Partners Master Fund, L.P., highlights sustained interest from key figures within GeneDx Holdings Corp. (NASDAQ:WGS), even as the company navigates a period of market volatility and operational challenges.
Between May 18 and May 20, 2026, the fund completed multiple transactions resulting in the acquisition of roughly 500,000 shares of GeneDx's Class A Common Stock. The cumulative value of these purchases reached $21,459,735. This buying pattern unfolded against a backdrop of notable stock price instability; while the equity had declined by 66% over the preceding six months, it concurrently posted a substantial 15% gain in its most recent trading week.
Transaction Details and Market Context
The purchasing activity was structured across three distinct dates. On May 18, 2026, the fund acquired 175,000 shares, with a weighted average price calculated at $42.5517 per share. The individual transaction prices for this day ranged between $42.4573 and $42.9153.
The subsequent day, May 19, 2026, saw the purchase of an additional 185,000 shares, achieving a weighted average price of $42.5964 per share. The pricing for these transactions varied from $42.1118 up to $42.6898.
Finally, on May 20, 2026, Casdin Partners Master Fund, L.P. completed the acquisition of 140,000 shares at a weighted average price of $43.8061 per share. The pricing spread for this final set of transactions was between $43.6287 and $44.3384.
From an external valuation perspective, the company maintains a market capitalization of $1.33 billion. Analysis from InvestingPro suggests that the stock is currently trading near its determined Fair Value.
Ownership Structure and Affiliations
The beneficial ownership related to these purchases is complex, involving several associated entities. The shares are directly held by Casdin Partners Master Fund, L.P., but the ultimate indirect beneficiaries include Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin. This connection is emphasized by the fact that Eli Casdin serves as the managing member for both Casdin Capital, LLC and Casdin Partners GP, LLC.
The current holdings picture shows that following these transactions, Casdin Partners Master Fund, L.P. indirectly holds a total of 3,507,164 shares of GeneDx Class A Common Stock. Additionally, Eli Casdin personally owns 20,517 shares directly. Furthermore, Casdin Partners GP, LLC maintains an indirect ownership stake of 19,247 shares, with Mr. Casdin acting as its managing member. Another related entity, CMLS Holdings LLC, whose Board of Managers includes Eli Casdin, indirectly holds 333,144 shares, and Mr. Casdin also possesses voting and investment discretion over these shares.
Recent Corporate Performance and Outlook
The timing of the fund's buying activity follows a period where GeneDx Holdings Corp. reported its first-quarter 2026 earnings, which fell short of analyst expectations. The company recorded an earnings per share (EPS) of -$0.28, missing the forecasted figure of -$0.01. Furthermore, revenue was reported at $102.3 million, falling below the anticipated $112.45 million.
These financial results prompted adjustments to price targets by major banking institutions. Both Canaccord and BTIG lowered their respective target prices for GeneDx. Specifically, Canaccord reduced its target to $75, while BTIG set its revised target at $90$. Despite these reductions, both firms maintained a Buy rating on the stock.
The reduction in price targets was attributed by analysts to a softer revenue outlook and muted expansion of test volume. Moreover, GeneDx proactively revised both its 2026 revenue and volume guidance downward. The company cited that an increased mix of genome tests relative to exome tests contributed to this adjustment, pointing to ongoing challenges associated with the reimbursement process for genome tests.
Despite these multiple financial headwinds and guidance revisions, some industry analysts have expressed a sentiment of cautious optimism regarding the strategic initiatives undertaken by GeneDx.